Summary by Moomoo AI
NeuroSense Therapeutics provided a business update and Q3 2024 financial results. The company completed its 18-month Phase 2b PARADIGM study for PrimeC in ALS, showing 33% slowed disease progression and 58% improved survival rates. NeuroSense received positive FDA feedback on Phase 3 study design and plans to commence in mid-2025.The company secured a $5M private placement and is pursuing early commercialization in Canada with potential launch in 2026. Q3 financials show R&D expenses of $4.61M, down 14% YoY, and G&A expenses of $3.52M. Cash position was $0.34M as of September 30, not including the December $5M financing.NeuroSense believes it has regained compliance with Nasdaq's $2.5M minimum shareholders' equity requirement. The company is progressing towards partnering opportunities for the Phase 3 study and Canadian market entry, with CEO Alon Ben-Noon stating they are approaching a key inflection point in development.
